Thursday, November 06, 2025
Zoom

Meeting Minutes

VOTING MEMBERS PRESENT:	G. Babcock, K. Burns, J. Corcoran, G. Dean, M. Espinola, S. Kasper, R. Larson, E. Otten, E. Serafin, T. Rausch, F. Schaefer
VOTING MEMBERS NOT PRESENT:	S. Apewokin, D. Elsaesser, J. Yu
AD HOC MEMBERS/CONSULTANTS/GUESTS:	T. Gulley, A. Perry
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 12:00 p.m.

I. **Conflicts of Interest** - No conflicts were identified.
II. **Minutes** - Minutes from the previous IBC meeting (10/02/25) were approved (11: YES/0: NO/0: Abstained)
III. **Old Business -** No old business was discussed
IV. **New Business**

A. **Primary Protocols** (3 protocols)

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-10-23-01	**Reighard**	New	BSL2	***In vitro*** and ***in vivo***: lentiviral and AAV vectors, HDM (microglial cells), *Escherichia coli* (RG1), plasmid DNA
IBC Requests:	**Main Form – General Safety**: 1. **Section I. A** and **I. B -** If you do not have a phone in your office, enter "N/A"; 2. **Section II. B** - Your Form A states that lentiviral vector is given to animals. If that is accurate, include the information in this section; 3. **Section III. B** - In additional info, indicate what type of sharps will be disposed of in sharp containers; 4. **Section III. B** - Check YES for "Additional Information" and indicate which activities involving biological hazardous materials are conducted inside of a fume hood; 5. **Section V** - Indicate in "Additional Information" when each of the selected disinfectants will be used. **Form A – Recombinant or Synthetic Nucleic Acid:** 6. **Section I** - Add any reporter genes (e.g., GFP, tdTomato, etc) in this section; 7. **Section II. B** - **#1 and #2** - According to your Research Abstract (Section II. B - Main Form), AAV is given to animals. If that is accurate, "in vivo" box needs to be checked; 8. **Section II. B- #3** - "Ecotropic" lentiviral vectors only have tropism to murine cells. If you need a vector able to infect human cells, it needs to be either amphotropic or pantropic; 9. **Section II. B** - **Helper Plasmids** - Even if the vector is ready-to-use, it is very important to know the type of envelope of a vector, especially upon an accidental exposure. Provide the type of envelope for this vector; 10. **Section III** - Uncheck box #4 and check box #5 to cover lentiviral vector work.			

	Form B – Microbial/Infectious Agents 11. "Name" should be limited to complete scientific name of the bacterium (i.e. *Escherichia coli*); 12. **Agent's Characteristics** - Include information about the agent's features (morphology, Gram stain etc) and add a statement regarding pathogenicity. **Form C – Human and NHP Derived Materials**: 13. **Section I -** Table - Select "*in vivo*" box and complete Section I. B that will appear once this box is checked. There, clarify whether the transduced/transfected HMC3 cells will be given to mice. **Form D – Biohazard in Animals:** 14. **Section II** - Check YES for "Additional Information" and provide the administration route for viral vectors, cells and plasmids; 15. **Section II** - In "Additional Information" indicate how long after the in vitro lentiviral vector transduction cells are transplanted into animals (less or longer than 72 hrs?); 16. **Section III. A** - Animals receiving plasmids does not need to be inoculated nor housed within the biocontainment. Please remove the sentence in this regard.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	**PI**	**Type of Submission**	**Biosafety Level**	**IBC Items**
2. 23-01-05-02	**Sah**	Amendment	BSL2	***in vivo:*** AAV vector **AMENDMENT:** ***in vivo****:* Recombinant Pseudorabies Virus
IBC Requests:	**Main Form – General Safety**: 1. **Section III. A** - Will you be using a centrifuge/Vortex or any other aerosol producing equipment in addition to pipettes? If so, please list them and include mitigation strategies for them; **Form B – Microbial/Infectious Agents** 2. The "Name" of the agent should read "Pseudorabies Virus"; 3. **Agent's Characteristics** - Describe the WT PRV, including clinical manifestations in humans; 4. ***In vivo* use** - Limit information to indicate the route(s) of administration. Details about the animal experiment can be provided in Form D. **Form D – Biohazard in Animals:** 5. **Section II** - Select "Viruses" and complete table (check the link on the top of table for information about containment) and in "Additional Information", describe the animal procedure involving PRV; 6. **Section III. C** - If animal procedures are performed exclusively in LAMS, uncheck the box for "bedding dump stations" since LAMS does not have this type of equipment; 7. **Section III. A** - Shedding for PRV almost certainly includes respiratory secretions as well, especially with lung as site of infection. Animals will likely shed until they die or are euthanized. Include this in this section and discuss that exposure to PRV can also occur during animal necropsy.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
3. 25-07-03-01	**Natarajan**	Amendment	BSL2	***in vitro*** *and* ***in vivo:*** HDM (cell lines) **AMENDMENT:** ***in vitro:*** Lentiviral Vector
IBC Requests:	**Main Form – General Safety**: 1. **Section I. C -** Include the phone number for Anish; **Form A – Recombinant or Synthetic Nucleic Acid:** 2. **Section I -** Include "GFP" as a separate entry and complete all related fields; 3. **#1. Viral Vector System** - Correct the typo – "Containes" to "contains"; 4. **Section II. B -** "Expression Construct" should be only "pLenti-C-mGFP-P2A-Puro" 5. **Section II. B** - If lentivirus transduced cells are given to animals, add it to this section. **Form D – Biohazard in Animals:** 6. **Section II -** Check YES for "Additional Information" and indicate how long after the in vitro lentiviral vector transduction cells are transplanted into animals (less or longer than 72 hrs?).			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

B. **Secondary Protocols** (8 protocols)

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-10-22	**Hassani**	New	BSL2	***in vitro:*** Recombinant nucleic acid (BSL1), yeast (RG1) ***in vitro*** and ***in vivo:*** HDM (established and primary cells)
IBC Requests:	1. Lab staff need to complete their BBP and BSC trainings: **Main Form – General Safety**: 2. **Section II. A** - Check the box for "Microbial Agents" to reflect use of yeast as expression system and the Box for "biohazard in live animals" to reflect animal experiments with human cells; 3. **Section II. B** - Include the rationale of using the materials selected in Section II. A; 4. **Section III. A** - **Vortex** - Remove info regarding pipettes/pipetting since there is a separate section for pipettes; 5. **Section III. A** - **Pipet** - Remove statements about vortex and describe what would be "pipetting technique" to mitigate aerosol production. For information on aerosol mitigation procedures, please consult the eManual (link provided on the top of this section); 6. **Section III. B -** In "Additional Information", indicate what type of needle safety devices (e.g. retractable needles) are used and what type of sharps are disposed of in sharps containers. Also, indicate what activities involving **biological** hazardous agents are conducted in a fume hood; 7. **Section III. C** - In "Additional Information", explain when safety goggles are used. **Form A – Recombinant or Synthetic Nucleic Acid:** 8. **Section I** - Check YES for "Additional Information" and describe the use of mRNA. Will it be linked to nanoparticles? 9. **Section II** - "Physical" delivery box should be selected instead. Please modify this section accordingly; 10. **Section I** - **Table** - Provide the names of cell suppliers; 11. **Section I. A** - Primary cells are either deidentified (no identification) or identified. Please revise this section.			

Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	**PI**	**Type of Submission**	**Biosafety Level**	**IBC Items**
2. 25-10-21-01	**McLeod**	New	BSL1	***in vitro:*** Recombinant nucleic acid (BSL1), *Escherichia coli* (RG1)
IBC Requests:	**Main Form – General Safety**: 1. **Section I. A -** Include the UC Mail code; 2. **Section I. B** - Include a secondary contact for your protocol. It can be a collaborator or an administrative person; 3. **Section I. C** - Include a phone number for Alena; 4. **Section II. B - #4** - For clarity, indicate what "others" are (enzymes? researchers?); 5. **Section III. A** - In addition to the information provided for the equipment listed, please include additional safety measures that need to be followed while performing activities with potential of aerosol generation. For information on aerosol mitigation procedures, please consult the eManual (link provided on the top of this section); 6. **Section III. B** - In additional info, include what type of sharps will be disposed of in sharps containers; 7. **Section III. C** - In ”Additional Information”, include when Face (surgical) Mask and safety goggles are being used. **Form A – Recombinant or Synthetic Nucleic Acid:** 8. **Section I - #1 and #2** - Natural function - Specify which type of metabolism genes are involved in; 9. **Section I - #2** - Select "expressed" and/or "inhibited"; 10. **Section I - #3** - In "Additional Information" indicate what is the "other" source of prok; 11. **Section III** - Select box #12. **Form B – Microbial/Infectious Agents** 12. "Name" of agent should be the expanded scientific name of the bacterium (Escherichia coli) only; 13. **Strain** - If you also use *E. coli* K12, include that in this field. Note that BL21 strain is not derived from K12; 14. **Agent's Characteristics** - Include a brief description of the bacterial species and strains, such as morphology and pathogenicity.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
3. 25-10-24-01	**Joiner**	New	BSL2	***in vitro:*** recombinant nucleic acid (BSL1), *Escherichia coli* (RG1), HDM (cell lines and iPSCs)

IBC Requests:	1. Lab staff need to complete their BBP and BSC trainings: **Main Form – General Safety**: 2. **Section I. A** and **I.B.** - Include UC mail code; 3. **Section II.B** - Include the rationale for the use of iPSCs and define acronyms throughout the section; 4. **Section III. B** - In "Additional Information" section, include what type of sharps will be disposed of in sharps containers; 5. **Section III. C** - Check YES for "Additional Information" and indicate when fluid resistant lab coat is used instead of a regular lab coat /gown; 6. **Section VIII -** This section is reserved for materials that are not being used in ongoing (nor in near-future planned) research. Please revise the section if necessary. **Form A – Recombinant or Synthetic Nucleic Acid:** 7. **Section I**- **#1** - Viral vector box was selected but the viral vector box was not checked in Section II. Make the necessary corrections; 8. **Section I**- **#1 and #2** - Check YES for "Additional Information" and indicate how genes are inhibited (e.g. shRNA, siRNA, miRNA, CRISPR/Cas9); 9. **Section I**- **#1 and #2** - Include some examples of the genes in those categories in Additional Information; 10. **Section I**- **#2** - In "Additional Information", indicate what "other gene source" and "other expression systems" are used. **Form B – Microbial/Infectious Agents** 11. "Name" of agent should be the expanded scientific name of the bacterium (Escherichia coli) only; 12. "Risk Group" should be "RG1" instead; 13. **Agent's Characteristics** - Include a brief description of the E. coli species and strains, such as morphology and pathogenicity; 14. If methanogenic Archaea is used, it should be listed in this form. **Form C – Human and NHP Derived Materials**: 15. **Section I - Table -** Confirm that human cells are used in animals (in vivo) since no information in this regard is provided throughout the protocol; 16. **Section I - Table** - Provide the source of listed cells; 17. Transfer information in Section II.B (*in vivo*) to Section II. A (*in vitro*) and describe why and how iPSCs are used.
Motion	Approve upon modifications addressing outlined issues.

Voting Result & **Dual Use**	**YES:** 10 *(One member did not vote)*	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
4. 25-10-22-01	**Ray**	New	BSL1	***in vitro***: HDM (cell lines), recombinant nucleic acid (BSL1), *Escherichia coli* (RG1)
IBC Requests:	**Main Form – General Safety**: 1. **Section I. A -** Include UC mail code; 2. **Section II. B** - **2nd sentence** - Provide the meaning of "HR"; 3. **Section VIII -** This section is reserved for materials that are not being used in ongoing or near-future planned research. Please revise the section if necessary. **Form A – Recombinant or Synthetic Nucleic Acid:** 4. **Section I- #2 -** Select "Expressed". **Form B – Microbial/Infectious Agents** 5. Complete the "Strain" field; 6. **Agent's Characteristics -** Remove the first paragraph and include information about the agent's features (morphology, Gram stain etc) add a statement regarding pathogenicity; **Form C – Human and NHP Derived Materials**: 7. **Section I - Table** - Indicate from where human cells are obtained.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
5. 25-10-07-01	**Guan**	Renewal	BSL2	***in vitro*** and ***in vivo:*** lentiviral, gamma-retroviral and adenoviral vectors, HDM (established cell lines: including virally transduced cells, breast tumor and Lymphangiosarcoma, and lymphatic malformation tissues) ***in vitro:*** *Escherichia coli* (RG1)
IBC Requests:	**Main Form – General Safety**: 1. **Section III. A -** Change 'vortexor' to 'vortexer'; 2. **Section III. A - Pipet** - Describe the "safe pipetting procedures" adopted in your lab. For information on aerosol mitigation procedures, please consult the eManual (link provided on the top of this section) 3. **Section III. B** - In additional info section, indicate what type of sharps will be discarded in sharps containers. **Form A – Recombinant or Synthetic Nucleic Acid:** 4. **Section II. B - #2** - Confirm that tag genes like GFP are inhibited; 5. **Section II** - "Physical" delivery box should be selected instead. **Form C – Human and NHP Derived Materials**: 6. **Section I** – **Table** – **Primary Cells** - Provide source of cells (clinical? vendor?); 7. **Section II. A** - Give examples of "biological agents" that cells are treated with and indicate how long after viral vector transduction flow cytometry occurs.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
6. 25-10-20-01	Park	Renewal	BSL2	***in vitro:*** *Staphylococcus aureus*, HDM (established and primary cells) ***in vitro*** and ***in vivo:*** AAV vector ***in vivo:*** Adenoviral vector
IBC Requests:	**Form A – Recombinant or Synthetic Nucleic Acid:** 1. **Section I - Gene #3** - Provide the "Natural Function" of Smad3 gene; 2. **Section I- #3** - In "Additional Information" state that siRNA is directly delivered with liposomes; 3. **Section II. A** - Indicate what "other Laboratory" provides viral vector and if they provide AAV and/or Adenovirus; 4. **Section II. B - System #1** - "Helper Plasmids" should also include the *rep* and *cap* plasmids. **Form D – Biohazard in Animals:** 5. **Section III. A** - Needlestick should be mentioned as a risk of personnel exposure; 6. **Section III. C** - In additional info, include what type of sharps will be discarded in the sharps containers.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
7. 25-10-20-03	**Li**	Renewal	BSL2	***in vitro***: HDM (established cell lines, tissues: skin, gingiva, nail plate, eye, and mandible)
IBC Requests:	**Main Form – General Safety**: 1. **Section I. B** - If secondary Contact does not have an office phone, enter "N/A"; 2. **Section I. D** - For clarity and to avoid confusion with animal satellite areas, indicate what occurs in CARE 5869; 3. **Section III. C** - **Additional Information** - Remove statement about face mask, if lab staff stopped wearing masks after the drop off of the UC COVID-19 mask requirement.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
8. 25-10-21-02	**Strobbia**	Renewal	BSL2	***in vitro:*** *Pseudomonas aeruginosa, Escherichia coli* (RG1), Tobacco Mosaic Virus, Soy Mosaic Virus, bacteriophage and HDM (exosomes)
IBC Requests:	1. Lab staff need to complete their BBP training; **Main Form – General Safety**: 2. **Section I. B -** Include Office/cell phone number and mail code for secondary contact; 3. **Section I. C** - Provide phone numbers for Authorized personnel;			

	4. **Section II. B** - **Project 1** - The term "Biosafety level" is related to facilities and practices while "Risk Group" is a classification used for agents. Therefore, "BSL1" should read "Risk Group 1" or "RG1" instead. Same request for the other projects; 5. **Section II. B** - Last paragraph should be "project 5" instead. Please revise it accordingly; 6. **Section III. A** - Will you not be using centrifuges, vortex, sonicator, pipets to process biological hazardous materials? If so, please include them along with mitigation plan to prevent aerosol exposure; 7. **Section III** - "BSL2" material should read "biohazardous material"; 8. **Section III. B** - **Additional Information** - Instead of classifying materials by their biosafety level, give examples of materials handled in fume hood and BSC; Also, in the third row you mention a "laminar flow cabinet". Please remove that if add that just as another name for biosafety cabinet; 9. **Section III. B** - **Last row** - Ethanol is not a sterilant. Replace "sterilized" with "disinfected"; 10. **Section III. C** - Replace "BSL1 and BSL2 materials" with "biohazardous materials"; 11. **Section VIII** - This section is reserved for materials that are not being used in ongoing (nor in the near-future planned) research. Please revise the section if necessary. **Form B – Microbial/Infectious Agents** 12. **Agent #1 & #2** - **Agent's Characteristics** - For clarity, first sentence should read "Virus is infectious to many plant species"; 13. **Agent #4 - Name** - To avoid confusion, remove "*Escherichia coli*"; 14. **Agent #5** - Check YES for "*in vitro*" and include information about bacterial culturing and further experiments with biofilm.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & **Dual Use**	**YES:** 11	**NO**: 0	**Abstained**: 0	**Dual Use**? No

V. Protocol Updates September 25th to October 29th - 17 protocols

1. IBC# 25-02-14-01 - PI: Drosatos - Personnel
2. IBC# 25-07-03-01 - PI: Natarajan - Amendment *in vitro* and *in vivo*: HDM (cell lines)-
3. IBC# 23-09-14-01 - PI: Schutte - Personnel
4. IBC# 24-10-14-01 - PI: MacLennan - Personnel
5. IBC# 24-03-11-01 - PI: Burns - Personnel
6. IBC# 25-04-15-01 - PI: Wise-Draper - Personnel
7. IBC# 24-08-21-02 - PI: Wasylishen - Personnel
8. IBC# 22-12-12-01 - PI: McReynolds - Personnel
9. IBC# 24-08-14-01 - PI: Conforti - Location
10. IBC# 24-04-16-02 - PI: Desai - Personnel, Secondary contact
11. IBC# 25-02-06-01 - PI: Berta - Personnel
12. IBC# 22-11-17-01 - PI: Kotagiri - BSL2 Amendment - *in vitro* and *in vivo*: *Lactobacillus plantarum*
13. IBC# 23-09-28-01 - PI: Zimmermann - Personnel and secondary contact
14. IBC# 24-10-10-01 - PI: Gao - Personnel
15. IBC# 24-03-13-01 - PI: Shirokawa - Personnel
16. IBC# 24-06-18-02 - PI: Hertlein - PI Reassignment (former Byrd), Personnel
17. IBC# 25-06-04-01 - PI: Steele - Personnel

VI. **Reports**

A. IBC/BSOf (M. Espinola)

REDCap: IBC application

- Arkansas Children's Research Institute is looking for a more user-friendly REDCap application for their protocols and asked if they could use ours.
- We will share our REDCap structure design with them.

VII. Educational Materials/Updates

A. **Public trust in science has declined since COVID — virologists need to unite around safety standards** Nature, October 2025

B. **MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness** WHO, October 2025

C. **New report warns of major biosecurity risks for the U.S.** NIH, October 2025

K. Burns adjourned the meeting at 12:32 p.m.